New heart ablation technique could tame dangerous rhythms in adults born with heart defects

NCT ID NCT06969378

Terminated Disease control Sponsor: Boston Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This trial investigates whether pulsed field ablation (PFA) can safely isolate the pulmonary veins in adults with congenital heart disease who experience atrial tachycardia. Participants will undergo PFA during a standard ablation procedure. The study measures how well the veins stay isolated and how long patients remain free from atrial arrhythmias.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pulsed field ablation using a pentaspline catheter
What this could lead to: If successful, this approach could offer a safer, more effective way to prevent atrial arrhythmias in adults with congenital heart disease.
What could go wrong: This is a small, early-stage trial without a control group, so results may not generalize. Risks include stroke, cardiac tamponade, and phrenic nerve injury.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation atrial flutter atrial tachycardia congenital heart disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION ATRIAL FLUTTER ATRIAL TACHYCARDIA CATHETER ABLATION CONGENITAL HEART DISEASE PULMONARY VEIN ISOLATION PULSED FIELD ABLATION

More trials for these conditions

Other studies related to the condition(s) this trial covers.